(ATAI) ATAI Life Sciences BV - Ratings and Ratios
Psychedelics, Depression, Anxiety, Addiction
ATAI EPS (Earnings per Share)
ATAI Revenue
Description: ATAI ATAI Life Sciences BV
ATAI Life Sciences BV is a clinical-stage biopharmaceutical company focused on developing innovative treatments for mental health disorders, including treatment-resistant depression, anxiety, and schizophrenia. The companys pipeline includes several promising candidates, such as BPL-003, RL-007, and ELE-101, which are in various stages of clinical trials.
From a strategic perspective, ATAIs focus on mental health treatments is timely, given the growing demand for effective therapies in this area. The companys use of novel formulations and mechanisms of action, such as intranasal delivery and serotonergic psychedelics, may provide a competitive edge. Key performance indicators (KPIs) to watch include the progression of its clinical trials, particularly the Phase 2a and 2b studies for BPL-003 and RL-007.
Some additional KPIs that may be relevant for ATAI include: - Cash runway: given the companys significant R&D expenses, its ability to fund ongoing trials and operations is crucial. - Partnerships and collaborations: strategic partnerships with larger pharmaceutical companies or research institutions could be a key factor in ATAIs success. - Regulatory milestones: progress with regulatory bodies, such as the FDA, will be critical in determining the companys ability to bring its treatments to market.
From a financial perspective, ATAIs market capitalization and lack of revenue raise concerns about its ability to sustain operations. The companys negative return on equity (RoE) of -102.40% is also a red flag. Investors should closely monitor ATAIs cash burn rate and ability to secure additional funding to support its R&D efforts.
ATAI Stock Overview
| Market Cap in USD | 823m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2021-06-18 |
ATAI Stock Ratings
| Growth Rating | -9.94% |
| Fundamental | 33.4% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 188% |
| Analyst Rating | 4.71 of 5 |
ATAI Dividends
Currently no dividends paidATAI Growth Ratios
| Growth Correlation 3m | 88% |
| Growth Correlation 12m | 78.6% |
| Growth Correlation 5y | -72.2% |
| CAGR 5y | -31.65% |
| CAGR/Max DD 5y | -0.33 |
| Sharpe Ratio 12m | -0.04 |
| Alpha | 181.41 |
| Beta | 1.525 |
| Volatility | 78.52% |
| Current Volume | 2821.9k |
| Average Volume 20d | 5649.8k |
| Stop Loss | 3.6 (-9.3%) |
| Signal | 2.80 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-119.4m TTM) > 0 and > 6% of Revenue (6% = 138.5k TTM) |
| FCFTA -0.44 (>2.0%) and ΔFCFTA -4.36pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 3341 % (prev 26.5k%; Δ -23.2kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.40 (>3.0%) and CFO -75.6m > Net Income -119.4m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 4.02 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (212.1m) change vs 12m ago 32.27% (target <= -2.0% for YES) |
| Gross Margin 92.85% (prev 10.05%; Δ 82.80pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 1.14% (prev 0.18%; Δ 0.97pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -30.81 (EBITDA TTM -88.6m / Interest Expense TTM 2.90m) >= 6 (WARN >= 3) |
Altman Z'' -30.78
| (A) 0.41 = (Total Current Assets 102.7m - Total Current Liabilities 25.5m) / Total Assets 189.2m |
| (B) -3.99 = Retained Earnings (Balance) -754.4m / Total Assets 189.2m |
| warn (B) unusual magnitude: -3.99 — check mapping/units |
| (C) -0.44 = EBIT TTM -89.3m / Avg Total Assets 202.5m |
| (D) -16.66 = Book Value of Equity -754.4m / Total Liabilities 45.3m |
| Total Rating: -30.78 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 33.38
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -10.49% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.18 = 2.48 |
| 5. Debt/Ebitda -0.29 = -2.50 |
| 6. ROIC - WACC -67.65% = -12.50 |
| 7. RoE -85.62% = -2.50 |
| 8. Rev. Trend 59.03% = 2.95 |
| 9. Rev. CAGR 244.3% = 2.50 |
| 10. EPS Trend 1.75% = 0.04 |
| 11. EPS CAGR 13.99% = 1.40 |
What is the price of ATAI shares?
Over the past week, the price has changed by +9.48%, over one month by +24.36%, over three months by +129.84% and over the past year by +230.08%.
Is ATAI Life Sciences BV a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ATAI is around 3.71 USD . This means that ATAI is currently overvalued and has a potential downside of -6.55%.
Is ATAI a buy, sell or hold?
- Strong Buy: 5
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ATAI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11.3 | 184.4% |
| Analysts Target Price | 8 | 101.5% |
| ValueRay Target Price | 4.2 | 6.8% |
Last update: 2025-08-17 02:08
ATAI Fundamental Data Overview
CCE Cash And Equivalents = 61.9m USD (Cash only, last quarter)
P/S = 356.4828
P/B = 5.7265
Beta = 1.552
Revenue TTM = 2.31m USD
EBIT TTM = -89.3m USD
EBITDA TTM = -88.6m USD
Long Term Debt = 19.7m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 6.16m USD (from shortLongTermDebt, last quarter)
Debt = 25.9m USD (Calculated: Short Term 6.16m + Long Term 19.7m)
Net Debt = 7.20m USD (from netDebt column, last fiscal year)
Enterprise Value = 787.1m USD (823.1m + Debt 25.9m - CCE 61.9m)
Interest Coverage Ratio = -30.81 (Ebit TTM -89.3m / Interest Expense TTM 2.90m)
FCF Yield = -10.49% (FCF TTM -82.5m / Enterprise Value 787.1m)
FCF Margin = -3574 % (FCF TTM -82.5m / Revenue TTM 2.31m)
Net Margin = -5171 % (Net Income TTM -119.4m / Revenue TTM 2.31m)
Gross Margin = 92.85% ((Revenue TTM 2.31m - Cost of Revenue TTM 165.0k) / Revenue TTM)
Tobins Q-Ratio = -1.04 (set to none) (Enterprise Value 787.1m / Book Value Of Equity -754.4m)
Interest Expense / Debt = 1.02% (Interest Expense 264.0k / Debt 25.9m)
Taxrate = 21.0% (US default)
NOPAT = -89.3m (EBIT -89.3m, no tax applied on loss)
Current Ratio = 4.02 (Total Current Assets 102.7m / Total Current Liabilities 25.5m)
Debt / Equity = 0.18 (Debt 25.9m / last Quarter total Stockholder Equity 143.7m)
Debt / EBITDA = -0.29 (Net Debt 7.20m / EBITDA -88.6m)
Debt / FCF = -0.31 (Debt 25.9m / FCF TTM -82.5m)
Total Stockholder Equity = 139.5m (last 4 quarters mean)
RoA = -63.11% (Net Income -119.4m, Total Assets 189.2m )
RoE = -85.62% (Net Income TTM -119.4m / Total Stockholder Equity 139.5m)
RoCE = -56.11% (Ebit -89.3m / (Equity 139.5m + L.T.Debt 19.7m))
RoIC = -56.35% (NOPAT -89.3m / Invested Capital 158.5m)
WACC = 11.30% (E(823.1m)/V(849.0m) * Re(11.63%)) + (D(25.9m)/V(849.0m) * Rd(1.02%) * (1-Tc(0.21)))
Shares Correlation 5-Years: 100.0 | Cagr: 14.53%
Discount Rate = 11.63% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -82.5m)
Revenue Correlation: 59.03 | Revenue CAGR: 244.3%
Rev Growth-of-Growth: 51.07
EPS Correlation: 1.75 | EPS CAGR: 13.99%
EPS Growth-of-Growth: -76.13
Additional Sources for ATAI Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle